Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CPI-613 + Metformin |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CPI-613 | CPI613|CPI 613|Devimistat | Devimistat (CPI-613) is an inhibitor of pyruvate dehydrogenase (PDH) and alpha-ketogluterate (KGDH), resulting in blockade of mitochondrial respiration which may lead to apoptosis and death of cancer cells (PMID: 29437791, PMID: 28495639, PMID: 32789692, PMID: 31512500). | ||
Metformin | Glucophage | Apo-Metformin | mTOR Inhibitor 51 | Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR and is FDA approved for type 2 diabetes (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05854966 | Phase II | CPI-613 + Metformin | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Withdrawn | 0 |